Poster
29
(#29) Healthcare Resource Utilization following Cariprazine Initiation among Medicare Beneficiaries with Bipolar I Disorder
Psych Congress 2025
Abstract: Introduction: Cariprazine is a dopamine D3 preferring D3/D2 and serotonin 5-HT1A receptor partial agonist atypical antipsychotic approved by the US Food and Drug Administration for schizophrenia, mania/mixed and depressive episodes in bipolar I disorder (BP-I), and the adjunctive treatment of Major Depressive Disorder(MDD). Real-world evidence of cariprazine use among Medicare Fee-for-Service (FFS) beneficiaries is limited. This study compares all-cause HCRU before vs. after cariprazine initiation in Medicare FFS beneficiaries with BP-I.
Methods: This retrospective observational study using administrative claims data included Medicare FFS beneficiaries ≥18 years with BP-I who initiated cariprazine January 1, 2019June 30, 2022 and had 6-months pre- and post-index continuous Medicare Parts A, B, and D enrollment. Post-index period spanned ≥6 months continuous cariprazine treatment from index date until earliest of: cariprazine discontinuation(≥45-day gap), other oral atypical antipsychotic exposure, long-acting injectable antipsychotic exposure, death, disenrollment, or study end. All-cause HCRU (inpatient, emergency room [ER], outpatient) was assessed during the 6-month pre- and post-index periods.
Results: The study included 1,655 beneficiaries. Proportion of ≥1 all-cause inpatient hospitalization (15.4% vs 10.3%, p 0.0001), mean all-cause hospitalizations (0.22 vs 0.14,p 0.0001), ≥1 all-cause ER visit ((41.3% vs 33.9%; p 0.0001) and mean number of ER visits (1.01 vs 0.77; p 0.0001) were significantly lower post- vs pre-index. Mean all-cause outpatient visits were not significantly different (22.62 vs 22.07,p>0.05).
Conclusions: Post-initiation, all-cause HCRU was significantly lower, highlighting cariprazine's economic value in reducing HCRU among Medicare FFS beneficiaries with BP-I.
Short Description: Based on administrative claims data, a lower proportion of Medicare Fee-for Service (FFS) beneficiaries with bipolar I disorder (BP-I) had inpatient hospital and emergency room care after initiating cariprazine versus before initiating cariprazine. Beneficiaries also had fewer number of inpatient hospital and emergency room visits on average after initiating cariprazine than before, but had similar number of outpatient visits than before.
Name of Sponsoring Organization(s): AbbVie Inc.
Methods: This retrospective observational study using administrative claims data included Medicare FFS beneficiaries ≥18 years with BP-I who initiated cariprazine January 1, 2019June 30, 2022 and had 6-months pre- and post-index continuous Medicare Parts A, B, and D enrollment. Post-index period spanned ≥6 months continuous cariprazine treatment from index date until earliest of: cariprazine discontinuation(≥45-day gap), other oral atypical antipsychotic exposure, long-acting injectable antipsychotic exposure, death, disenrollment, or study end. All-cause HCRU (inpatient, emergency room [ER], outpatient) was assessed during the 6-month pre- and post-index periods.
Results: The study included 1,655 beneficiaries. Proportion of ≥1 all-cause inpatient hospitalization (15.4% vs 10.3%, p 0.0001), mean all-cause hospitalizations (0.22 vs 0.14,p 0.0001), ≥1 all-cause ER visit ((41.3% vs 33.9%; p 0.0001) and mean number of ER visits (1.01 vs 0.77; p 0.0001) were significantly lower post- vs pre-index. Mean all-cause outpatient visits were not significantly different (22.62 vs 22.07,p>0.05).
Conclusions: Post-initiation, all-cause HCRU was significantly lower, highlighting cariprazine's economic value in reducing HCRU among Medicare FFS beneficiaries with BP-I.
Short Description: Based on administrative claims data, a lower proportion of Medicare Fee-for Service (FFS) beneficiaries with bipolar I disorder (BP-I) had inpatient hospital and emergency room care after initiating cariprazine versus before initiating cariprazine. Beneficiaries also had fewer number of inpatient hospital and emergency room visits on average after initiating cariprazine than before, but had similar number of outpatient visits than before.
Name of Sponsoring Organization(s): AbbVie Inc.
